Josh Bilenker, Endpoints JPM 2020 (Jeff Rumans)

Josh Bilenker ends his brief role in an un­usu­al ex­per­i­ment at Eli Lil­ly, bow­ing out as head of their Loxo can­cer R&D unit

A lit­tle more than a year since Josh Bilenker start­ed an un­usu­al ex­per­i­ment run­ning Eli Lil­ly’s can­cer re­search group fol­low­ing the $8 bil­lion sale of his start­up Loxo to the phar­ma gi­ant, the biotech en­tre­pre­neur is wrap­ping up his part in the ven­ture.

Lil­ly ex­ecs not­ed in their quar­ter­ly call to­day that Bilenker has opt­ed to leave Loxo On­col­o­gy at Lil­ly in pur­suit of oth­er, un­spec­i­fied, en­deav­ors. In his place will be Ja­cob Van Naar­den, Bilenker’s lieu­tenant among the group tapped to take up the reins of on­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.